Uncontrolled diabetes among older adults with preclinical heart failure (HF) stages appears to increase the risk of HF progression, suggests a study.
A total of 4,774 adults (mean age 75.4 years, 58 percent women) with preclinical HF (stage A, n=1,551 or stage B, n=3,223) who attended the Atherosclerosis Risk In Communities (ARIC) study visit 5 (2011‒2013) were included in this study, which sought to characterize the influence of diabetes on the progression from preclinical HF stages (A or B based on the 2021 Universal Definition) to overt HF.
The authors evaluated within each stage the association of diabetes and glycaemic control (haemoglobin A1c [HbA1c] <7 percent vs ≥7 percent) with progression to HF, as well as that of cross-categories of HF stage, diabetes, and glycaemic control with incident HF.
A total of 470 HF events occurred among participants during 8.6 years of follow-up. Stage B participants with HbA1c ≥7 percent had clinical HF at a younger age compared to those with controlled or without diabetes (mean age 80 vs 83 vs 82 years; p<0.001).
HbA1c ≥7 percent showed a more robust correlation with HF in stage B (hazard ratio [HR], 1.83, 95 percent confidence interval [CI], 1.33‒2.51) than in stage A (HR, 1.52, 95 percent CI, 0.53‒4.38).
In cross-categories of preclinical HF stage and HbA1c, participants with stage B and HbA1c ≥7 percent had an increased HF progression risk relative to those with stage A without diabetes (HR, 7.56, 95 percent CI, 4.68‒12.20).
“Our results suggest that targeting diabetes early in the HF process is critical,” the authors said.